HealthMarch 30, 2026

Creatinine Clearance Calculator Guide: Cockcroft-Gault Formula

By The hakaru Team·Last updated March 2026

Medical Disclaimer: This guide is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Never use online calculators to make clinical dosing decisions without consulting a licensed healthcare professional. Creatinine clearance estimates have limitations and should be interpreted in the context of the full clinical picture.

Quick Answer

  • *Cockcroft-Gault: CrCl = [(140 – age) × weight (kg)] ÷ [72 × serum creatinine (mg/dL)]. Multiply by 0.85 for females.
  • *Normal CrCl: 97–137 mL/min (males) and 88–128 mL/min (females).
  • *CrCl declines roughly 6.5 mL/min per decade after age 20 as part of normal aging.
  • *Most drug labels use Cockcroft-Gault (not CKD-EPI) for renal dose adjustments.

What Is Creatinine Clearance?

Creatinine clearance (CrCl) estimates how efficiently the kidneys filter creatinine — a waste product from muscle metabolism — out of the blood. It serves as a proxy for kidney function and is measured in milliliters per minute (mL/min).

According to the National Kidney Foundation, approximately 37 million American adults have chronic kidney disease (CKD), and 9 in 10 do not know they have it. CrCl estimation is one of the primary screening tools for detecting reduced kidney function early.

The Cockcroft-Gault Equation

Published by Donald Cockcroft and Henry Gault in 1976 in the journal Nephron, this equation remains the most widely used formula for estimating CrCl in clinical practice, particularly for drug dosing. It has been cited over 25,000 times (Google Scholar, 2025), making it one of the most-cited papers in nephrology.

CrCl (mL/min) = [(140 – age) × weight (kg)] ÷ [72 × SCr (mg/dL)]

For female patients, multiply the result by 0.85 to account for lower average muscle mass and creatinine production.

Worked Example: Male Patient

A 65-year-old male weighing 80 kg with a serum creatinine of 1.2 mg/dL:

CrCl = [(140 – 65) × 80] ÷ [72 × 1.2]
CrCl = [75 × 80] ÷ [86.4]
CrCl = 6,000 ÷ 86.4
CrCl = 69.4 mL/min

Worked Example: Female Patient

A 72-year-old female weighing 60 kg with a serum creatinine of 0.9 mg/dL:

CrCl = [(140 – 72) × 60] ÷ [72 × 0.9] × 0.85
CrCl = [68 × 60] ÷ [64.8] × 0.85
CrCl = 4,080 ÷ 64.8 × 0.85
CrCl = 62.96 × 0.85
CrCl = 53.5 mL/min

Normal CrCl Ranges by Age

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CrCl varies by age and sex:

AgeMales (mL/min)Females (mL/min)
20–2997–13788–128
30–3991–13082–121
40–4985–12375–115
50–5978–11669–108
60–6972–11064–100
70–7965–10358–93
80+58–9652–86

A healthy kidney filters roughly 120 mL/min at age 20. By age 80, that drops to approximately 60–70 mL/min even without disease. This age-related decline is why the Cockcroft-Gault equation includes age as a variable.

CKD Staging Based on GFR

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines classify CKD into stages based on GFR. While CrCl is not identical to GFR, it provides a reasonable approximation:

StageGFR (mL/min/1.73m²)Description
1≥90Normal or high
260–89Mildly decreased
3a45–59Mild to moderately decreased
3b30–44Moderately to severely decreased
415–29Severely decreased
5<15Kidney failure

According to the CDC, CKD stage 3 or higher affects approximately 6.2% of the U.S. adult population (National Health and Nutrition Examination Survey, 2024).

CrCl vs. eGFR: Which Should You Use?

There are two main equations for estimating kidney function, and they serve different purposes:

FeatureCockcroft-Gault (CrCl)CKD-EPI (eGFR)
Published19762009 (updated 2021)
Uses weight?YesNo
Output unitmL/minmL/min/1.73m²
Primary useDrug dosingCKD staging
FDA drug labelsYes (most)Rarely

A 2023 study in the American Journal of Kidney Diseases found that using CKD-EPI instead of Cockcroft-Gault for drug dosing led to different dose recommendations in 25–40% of patients, particularly in the elderly and obese. This is why matching the equation to the drug label matters.

Weight Considerations for Obese Patients

The original Cockcroft-Gault study used total body weight. However, adipose tissue does not produce creatinine at the same rate as lean muscle. For patients more than 20% above their ideal body weight (IBW), most pharmacists use adjusted body weight (ABW):

ABW = IBW + 0.4 × (Actual Weight – IBW)

Where ideal body weight is calculated as:

  • Males: IBW = 50 + 2.3 × (height in inches – 60)
  • Females: IBW = 45.5 + 2.3 × (height in inches – 60)

According to a 2022 meta-analysis in Clinical Pharmacokinetics, using ABW in the Cockcroft-Gault equation produced estimates within 10% of measured CrClin obese patients, compared to 30–40% overestimation with actual body weight.

Limitations of the Cockcroft-Gault Equation

Extremes of Body Size

The equation was derived from a study of 249 male patients. It performs less reliably at extremes of body weight (BMI <18.5 or >40), in amputees, and in patients with rapidly changing renal function.

Unstable Creatinine

CrCl estimation assumes steady-state serum creatinine. In acute kidney injury, where creatinine is rising or falling rapidly, the equation significantly misestimates true clearance. Clinical judgment and trending values are needed.

Low Muscle Mass

Elderly, malnourished, or cachectic patients may have low serum creatinine due to reduced muscle mass, making their estimated CrCl appear falsely normal. A serum creatinine of 0.6 mg/dL in an 85-year-old may not mean good kidney function.

Diet and Supplements

High protein intake and creatine supplements can transiently raise serum creatinine without reflecting true kidney function changes. Cooked meat contains creatinine; a large steak dinner can temporarily increase levels by 0.1–0.3 mg/dL.

Estimate creatinine clearance quickly

Use our free Creatinine Clearance Calculator →
Disclaimer:This guide is for educational and informational purposes only. It does not constitute medical advice. Creatinine clearance estimates should be interpreted by a qualified healthcare professional in the context of the patient's full clinical picture. Do not adjust medications based solely on calculator results.

Frequently Asked Questions

What is the Cockcroft-Gault equation?

The Cockcroft-Gault equation estimates creatinine clearance (CrCl) using age, weight, serum creatinine, and sex. The formula is: CrCl = [(140 – age) × weight in kg] ÷ [72 × serum creatinine in mg/dL]. For females, multiply the result by 0.85. It was published in 1976 and remains the standard for drug dosing adjustments.

What is a normal creatinine clearance?

Normal creatinine clearance is approximately 97–137 mL/min for males and 88–128 mL/min for females. CrCl naturally declines with age, decreasing by roughly 6.5 mL/min per decade after age 20. A 70-year-old with a CrCl of 70 mL/min may be within the normal range for their age.

What is the difference between CrCl and GFR?

Creatinine clearance (CrCl) measures how quickly the kidneys clear creatinine from the blood and slightly overestimates true kidney function because some creatinine is secreted by the tubules. GFR (glomerular filtration rate) is the gold standard measure of kidney function. The CKD-EPI equation estimates GFR (eGFR), while Cockcroft-Gault estimates CrCl. Most drug labels use CrCl for dosing recommendations.

Should I use actual body weight or ideal body weight?

For patients within 20% of their ideal body weight (IBW), use actual body weight. For obese patients (more than 20% above IBW), use adjusted body weight: ABW = IBW + 0.4 × (actual weight – IBW). Using actual weight in obese patients overestimates CrCl because adipose tissue does not produce creatinine proportionally to lean mass.

Why do drug labels use Cockcroft-Gault instead of CKD-EPI?

Most drugs were studied and approved using Cockcroft-Gault because it was the standard when the clinical trials were conducted. The FDA does not require manufacturers to update labels with newer equations. As a result, pharmacists and clinicians use Cockcroft-Gault for dose adjustments to match the evidence base from the original drug trials.